ClinicalTrials.gg
Not yet recruitingNCT06805266Updated Feb 6, 2025

Vortioxetine for Depressive Symptoms and Freezing of Gait in Parkinson Disease

A Phase 4 interventional study of Vortioxetine (tablet) in Parkinson Disease, Idiopathic, Freezing of Gait and Depression Not Otherwise Specified, sponsored by Marianna Amboni. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-02-06.

Sponsored by Marianna Amboni · Phase 4, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
40
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

The present study involves patients with Parkinson Disease (PD) suffering from freezing of gait (FOG) and depressive symptoms. The main aim of the study is evaluating the efficacy of vortioxetine in reducing moderate/severe FOG not responsive to dopaminergic treatment in patients with PD with depressive symptoms.

Read the detailed description

Depression and anxiety are common in patients with Parkinson's disease (PD). In PD, several drugs, such as dopamine-agonists, inhibitors of serotonin uptake (SSRI), tricyclic antidepressants (TCAs) and norepinephrine uptake inhibitors (SNRI) are effective in treating depressive symptoms. Recently, a Delphi consensus has concluded that multimodal drugs, like vortioxetine, are good treatment options for depression in PD and an open-label prospective study has shown that the vortioxetine may improve depressive symptoms and cognition in PD patients with major depression Vortioxetine has different mechanisms of action; it is a serotonin transporter (SERT) inhibitor, an antagonist of 5-HT3, 5-HT7, 5-HTID, a partial agonist of 5-HT1B and a full agonist of 5-HT1A. Moreover, despite vortioxetine does not interact significantly with the norepinephrine transporters or dopamine transporters, it has been shown to increase extracellular levels of norepinephrine, dopamine, and non-monoamine neurotransmitters including acetylcholine. These effects are likely related to the interaction between vortioxetine and various serotonin receptors.

Depression and anxiety or panic attacks are commonly associated to freezing of gait (FOG) in PD. FOG is a disabling symptom of parkinsonian syndromes, whose pathophysiology is heterogeneous and partly unclear. The relationship between FOG and dopaminergic treatment is rather complex. Based on response to dopaminergic treatment, FOG may be responsive, unresponsive (or partially responsive) or induced by dopaminergic drugs. FOG, especially unresponsive FOG, is commonly associated with cognitive dysfunction, namely attentional-executive and visuospatial alterations in PD patients. Since FOG episodes might be related to the Off state and/or to dopaminergic underdosing in PD, the first treatment option should be the increase of dopaminergic drugs dose, when possible. FOG episodes that are less responsive or nonresponsive to dopaminergic treatment represent the greatest therapeutic challenge. Beyond dopaminergic pathway, non-dopaminergic networks, i.e. noradrenergic and cholinergic transmission, may play a role in the pathogenesis of FOG. We hypothesize that vortioxetine might be effective in treating FOG by enhancing both monoamine and non-monoamine neurotransmitters.

STUDY DESIGN Clinical evaluation will be performed during optimal on state of patients

VISIT 1:

  1. Enrolment: Informed consent signature
  2. Standardized gait analysis with wearable sensors:

    Patients will be videotaped and assessed with wearable sensors (Opal) while:

    A) Performing the Rating Instrument to Assess Festination and Freezing Gait in Parkinsonian Patients (RIAFFGPP) . In RIAFFGPP patients have to:

    i. Sit down on a chair set up in front of a door. ii. After 30 s, stand up and walk to a floor mark (40 x 40 cm) iii. Perform within the mark two 360° turns, clockwise (cw) and counter-clockwise (ccw) iiii. Open and walk through the door, turn outside, and come back to the chair

    B) Walking forward along a 10 m path during three conditions:

    i. self paced velocity ii. fastest as possible without running pace iii. self paced velocity with mental task (seven serial subtraction from 100 - counting aloud)

  3. Clinical Global Impression scale (patient and clinician)
  4. FOG Questionnaire referred to the on state
  5. New freezing of gait questionnaire (NFOG-Q)
  6. Falls Efficacy Scale
  7. Cognitive function assessment:

    • MMSE
    • MoCA
    • FiPaT
    • Raven Progressive Matrices
    • The Benton Judgment of Line Orientation Test (JLOT)
    • Rey auditory 15-word learning test
    • Babcock story (episodic memory)
    • Rey Complex Figure (copy and recall)
    • Stroop test
    • Trial making test
    • Cancellation attentional matrices
    • Phonological verbal fluency
    • Semantic verbal fluency
    • Frontal Assessment Battery
    • Constructional Apraxia
    • SAND-Denomination
  8. MDS-UPDRS
  9. BDI-II
  10. NPI
  11. Apathy Scale
  12. PDQ-8
  13. Blood pressure, heart rate
  14. Instruction to fill in a falls diary for the next 2 weeks

VISIT 2 (Start of treatment, after 14 days ± 3 days from Visit 1)

  1. Enrolled patients will start vortioxetine:

    Vortioxetine Schedule:

    Vortioxetine 5 mg: once a day after lunch for one week, After one week, Vortioxetine 10 mg once a day

  2. Instruction on filling in again a falls diary:

Four weeks after starting medication patients will fill in again a falls diary for the next 2 consecutive weeks

VISIT 3 (after 12 weeks ± 7 days from ):

  1. Standardized gait analysis with wearable sensors (see visit 1)

    • RIAFFGPP
    • Walking forward along a 10 m path during three conditions
  2. Clinical Global Impression scale (patient and clinician)
  3. FOG Questionnaire
  4. New freezing of gait questionnaire (NFOG-Q)
  5. Falls Efficacy Scale
  6. Cognitive function assessment (see visit 1)
  7. MDS-UPDRS or
  8. BDI-II
  9. NPI
  10. Apathy Scale
  11. PDQ-8
  12. Blood pressure, heart rate
  13. Adverse events
02

Conditions studied

  • Parkinson Disease, Idiopathic
  • Freezing of Gait
  • Depression Not Otherwise Specified

Keywords

  • Parkinson Disease
  • freezing of gait
  • depression NOS
03

In context

Parkinson Disease

4,583 studies on the registry are indexed under Parkinson Disease; 1,086 are open to participants now.

This study's planned enrollment of 40 is close to the median of 40 across 3,360 interventional studies indexed under Parkinson Disease.

Browse Parkinson Disease studies →

Lead sponsor

This is the only study on the registry with Marianna Amboni as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Diagnosis of PD according to published criteria
  2. Occurrence of depression according to Beck Depression Inventory II (score ≥ 15)
  3. A score ≥ 2 on the freezing question #2.13 of part 2 of the MDS-UPDRS (moderate-severe FOG).
  4. FOG not responsive to dopaminergic treatment.

Exclusion criteria

Exclusion Criteria:

  1. Treatment with IMAO-B (rasagiline, selegiline, safinamide) (to be included, IMAO-B need to be withdrawn for at least 15 days)
  2. Concomitant treatment with other antidepressant drugs
  3. Hepatic and renal insufficiency
  4. Treatment with tramadol or triptans
  5. Psychotic disorder
  6. Dementia according to
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    FOG-PD

    FOG-PD will receive vortioxetine

    Drug: Vortioxetine (tablet)

Interventions

  • DrugVortioxetineStudies of VortioxetineVortioxetine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Vortioxetine will be used with the aim of treating freezing of gait in subjects with Parkinson Disease and depressive symptoms

06

What researchers measure

Primary outcomes

  1. Change in the score of the Freezing Of Gait (FOG) Questionnaire referred to the "on state"

    Total score of FOG Questionnaire ranges from 0 to 24 and higher scores correspond to more severe FOG

    Time frame: From enrollment to the end of treatment at 12 weeks

Secondary outcomes

  1. Change on severity of FOG not responsive to dopaminergic treatment in patients with PD.

    Change on duration (seconds) of FOG episodes on standardized gait analysis with wearable sensors

    Time frame: From enrollment to the end of treatment at 12 weeks

  2. Chenage on frequency of FOG not responsive to dopaminergic treatment in patients with PD.

    Change on number of FOG episodes on standardized gait analysis with wearable sensors

    Time frame: From enrollment to the end of treatment at 12 weeks

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • Ziegler K, Schroeteler F, Ceballos-Baumann AO, Fietzek UM. A new rating instrument to assess festination and freezing gait in Parkinsonian patients. Mov Disord. 2010 Jun 15;25(8):1012-8. doi: 10.1002/mds.22993. PubMed 20310009 ↗
  • Santos Garcia D, Alonso Losada MG, Cimas Hernando I, Cabo Lopez I, Yanez Bana R, Alonso Redondo R, Paz Gonzalez JM, Cores Bartolome C, Feal Painceiras MJ, Iniguez Alvarado MC, Labandeira C, Garcia Diaz I. Vortioxetine Improves Depressive Symptoms and Cognition in Parkinson's Disease Patients with Major Depression: An Open-Label Prospective Study. Brain Sci. 2022 Oct 29;12(11):1466. doi: 10.3390/brainsci12111466. PubMed 36358393 ↗
  • Nieuwboer A, Rochester L, Herman T, Vandenberghe W, Emil GE, Thomaes T, Giladi N. Reliability of the new freezing of gait questionnaire: agreement between patients with Parkinson's disease and their carers. Gait Posture. 2009 Nov;30(4):459-63. doi: 10.1016/j.gaitpost.2009.07.108. Epub 2009 Aug 5. PubMed 19660949 ↗
  • Bloem BR, Marinus J, Almeida Q, Dibble L, Nieuwboer A, Post B, Ruzicka E, Goetz C, Stebbins G, Martinez-Martin P, Schrag A; Movement Disorders Society Rating Scales Committee. Measurement instruments to assess posture, gait, and balance in Parkinson's disease: Critique and recommendations. Mov Disord. 2016 Sep;31(9):1342-55. doi: 10.1002/mds.26572. Epub 2016 Mar 4. PubMed 26945525 ↗
  • Bang-Andersen B, Ruhland T, Jorgensen M, Smith G, Frederiksen K, Jensen KG, Zhong H, Nielsen SM, Hogg S, Mork A, Stensbol TB. Discovery of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): a novel multimodal compound for the treatment of major depressive disorder. J Med Chem. 2011 May 12;54(9):3206-21. doi: 10.1021/jm101459g. Epub 2011 Apr 12. PubMed 21486038 ↗
  • Amboni M, Stocchi F, Abbruzzese G, Morgante L, Onofrj M, Ruggieri S, Tinazzi M, Zappia M, Attar M, Colombo D, Simoni L, Ori A, Barone P, Antonini A; DEEP Study Group. Prevalence and associated features of self-reported freezing of gait in Parkinson disease: The DEEP FOG study. Parkinsonism Relat Disord. 2015 Jun;21(6):644-9. doi: 10.1016/j.parkreldis.2015.03.028. Epub 2015 Apr 13. PubMed 25899545 ↗
  • Amboni M, Cozzolino A, Longo K, Picillo M, Barone P. Freezing of gait and executive functions in patients with Parkinson's disease. Mov Disord. 2008 Feb 15;23(3):395-400. doi: 10.1002/mds.21850. PubMed 18067193 ↗
  • Aguera-Ortiz L, Garcia-Ramos R, Grandas Perez FJ, Lopez-Alvarez J, Montes Rodriguez JM, Olazaran Rodriguez FJ, Olivera Pueyo J, Pelegrin Valero C, Porta-Etessam J. Focus on Depression in Parkinson's Disease: A Delphi Consensus of Experts in Psychiatry, Neurology, and Geriatrics. Parkinsons Dis. 2021 Feb 8;2021:6621991. doi: 10.1155/2021/6621991. eCollection 2021. PubMed 33628415 ↗

Individual participant data

Plan to share: Yes — Clinical and outcome measures

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: For 12 months after the completation of the study

Access criteria: contacting Central Contact Person by email on mamboni@unisa.it

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Feb 2025; primary completion for Dec 2026, 22 months later.

Of 42 non-industry phase 4 interventional studies under Parkinson Disease, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 75. This study's planned 22 months is below that.

Counting every sponsor, half of 57 studies reached it within 28 months; a quarter within 19 and three quarters within 65.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 16, 2025
First posted
Feb 3, 2025
StartEst.
Feb 2025
Primary completionEst.
Dec 2026
CompletionEst.
Feb 2027
Last update
Feb 6, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 6, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06805266
Lead sponsor
Marianna Amboni
Responsible party
Marianna Amboni (Professor, University of Salerno) — Sponsor-investigator
First posted
Feb 3, 2025
Start date
Feb 2025 (estimated)
Primary completion
Dec 2026 (estimated)
Completion
Feb 2027 (estimated)
Last update
Feb 6, 2025

Study contacts

Marianna Amboni, Professor
Contact
mamboni@unisa.it
+393358274695
Federico Di Filippo, Doctor
Contact
federicodifilippo@hotmail.it
+393519398297

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Vortioxetine

Start the discussion